【卫材(ESALY.US)/渤健(BIIB.US)阿尔茨海默病新药申报上市可在家中自己注射】智通财经APP获悉，5月14日，卫材(Eisai/ESALY.

智通财经05-15

【卫材(ESALY.US)/渤健(BIIB.US)阿尔茨海默病新药申报上市可在家中自己注射】智通财经APP获悉，5月14日，卫材(Eisai/ESALY.US)和渤健(Biogen/BIIB.US)宣布，卫材已开始向美国FDA提交皮下注射仑卡奈单抗(lecanemab)的滚动生物制剂许可申请(BLA)，适用于治疗早期阿尔茨海默患者(轻度认知障碍或轻度痴呆阶段患者)。该产品此前已经获FDA授予...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2435363097?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-05-15 21:05","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2435363097","market":"us","top_or_hot":-1,"title":"【卫材(ESALY.US)/渤健(BIIB.US)阿尔茨海默病新药申报上市 可在家中自己注射】智通财经APP获悉，5月14日，卫材(Eisai/ESALY.","media":"智通财经","content":"<div>\n<p>【卫材(ESALY.US)/渤健(BIIB.US)阿尔茨海默病新药申报上市 可在家中自己注射】智通财经APP获悉，5月14日，卫材(Eisai/ESALY.US)和渤健(Biogen/BIIB.US)宣布，卫材已开始向美国FDA提交皮下注射仑卡奈单抗(lecanemab)的滚动生物制剂许可申请(BLA)，适用于治疗早期阿尔茨海默患者(轻度认知障碍或轻度痴呆阶段患者)。该产品此前已经获FDA授予...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-15 21:05 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【卫材(ESALY.US)/渤健(BIIB.US)阿尔茨海默病新药申报上市 可在家中自己注射】智通财经APP获悉，5月14日，卫材(Eisai/ESALY.US)和渤健(Biogen/BIIB.US)宣布，卫材已开始向美国FDA提交皮下注射仑卡奈单抗(lecanemab)的滚动生物制剂许可申请(BLA)，适用于治疗早期阿尔茨海默患者(轻度认知障碍或轻度痴呆阶段患者)。该产品此前已经获FDA授予...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2435363097","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2435363097","pubTimestamp":1715778336,"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【卫材(ESALY.US)/渤健(BIIB.US)阿尔茨海默病新药申报上市 可在家中自己注射】智通财经APP获悉，5月14日，卫材(Eisai/ESALY.US)和渤健(Biogen/BIIB.US)","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4532":"文艺复兴科技持仓","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","BIIB":"渤健公司","BK4139":"生物科技","BK4588":"碎股","BLA.AU":"Blue Sky Alternative Inv","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"[Eisai (ESALY.US)/Biogen (BIIB.US) new Alzheimer's disease drug declared for marketing and can be injected at home] Zhitong Finance APP learned that on May 14, Eisai (Eisai/ESALY.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"BLA.AU":1},"content_text":"【卫材(ESALY.US)/渤健(BIIB.US)阿尔茨海默病新药申报上市 可在家中自己注射】智通财经APP获悉，5月14日，卫材(Eisai/ESALY.US)和渤健(Biogen/BIIB.US)宣布，卫材已开始向美国FDA提交皮下注射仑卡奈单抗(lecanemab)的滚动生物制剂许可申请(BLA)，适用于治疗早期阿尔茨海默患者(轻度认知障碍或轻度痴呆阶段患者)。该产品此前已经获FDA授予快速通道资格，适用于已完成双周静脉注射起始阶段的患者后续接受每周一次皮下注射，以维持有效的药物浓度。如果获得FDA批准，该产品可在家中给药，且注射时间比静脉注射所需的时间更短。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435363097"}

【卫材(ESALY.US)/渤健(BIIB.US)阿尔茨海默病新药申报上市 可在家中自己注射】智通财经APP获悉，5月14日，卫材(Eisai/ESALY.

精彩评论

【卫材(ESALY.US)/渤健(BIIB.US)阿尔茨海默病新药申报上市可在家中自己注射】智通财经APP获悉，5月14日，卫材(Eisai/ESALY.